Haemonetics Net Income From Continuing Ops from 2010 to 2026
| HAE Stock | USD 64.22 0.09 0.14% |
Net Income From Continuing Ops | First Reported 2000-06-30 | Previous Quarter 38.7 M | Current Value 44.7 M | Quarterly Volatility 17.3 M |
Review Haemonetics financial statements over time to add context on performance and capital structure. Key drivers include Interest Expense of 13.7 M, Total Revenue of 1.6 B or Gross Profit of 940.1 M along with ratios such as Price To Sales Ratio of 2.14, Dividend Yield of 0.0098 or PTB Ratio of 2.81. This view complements Haemonetics Valuation and Volatility modules.
Haemonetics | Net Income From Continuing Ops | Build AI portfolio with Haemonetics Stock |
Analyzing Haemonetics's Net Income From Continuing Ops over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income From Continuing Ops has evolved provides context for assessing Haemonetics's current valuation and future prospects.
Latest Haemonetics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Haemonetics over the last few years. It is Haemonetics' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Haemonetics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Haemonetics Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 73,633,308 | |
| Geometric Mean | 66,826,572 | |
| Coefficient Of Variation | 94.88 | |
| Mean Deviation | 52,099,974 | |
| Median | 66,886,000 | |
| Standard Deviation | 69,862,981 | |
| Sample Variance | 4880.8T | |
| Range | 258.1M | |
| R-Value | 0.71 | |
| Mean Square Error | 2617.7T | |
| R-Squared | 0.50 | |
| Significance | 0.0016 | |
| Slope | 9,755,351 | |
| Total Sum of Squares | 78093.4T |
Haemonetics Net Income From Continuing Ops History
Haemonetics Valuation Analysis
Haemonetics is a large-cap equity in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care categories. Valuation integrates earnings durability and capital efficiency. Defensive traits reduce macro sensitivity. We review the company from a portfolio-construction standpoint emphasizing diversification and stability.
Methodology
Unless otherwise specified, financial data for Haemonetics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Haemonetics (USA Stocks:HAE) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
Macroaxis analytics incorporate public filings and market reference sources and official disclosures from U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Data harmonization may result in minor timing offsets. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Haemonetics is covered by 11 analysts. 5 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Goldman Sachs, UBS Investment Research, Bank of America Securities, RBC Capital Markets, Jefferies, J.P. Morgan, among others. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Haemonetics Stock Analysis
A structured review of Haemonetics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Haemonetics Stock. Outlined below are key reports that provide context for Haemonetics Stock:Review Haemonetics Correlation against competitors for Haemonetics. This adds peer-relative context. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.Analysis related to Haemonetics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Quarterly Earnings Growth 0.284 | Earnings Share 3.63 | Revenue Per Share | Quarterly Revenue Growth -0.03 | Return On Assets |
The market value of Haemonetics is measured differently than book value, which reflects Haemonetics accounting equity. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Market price can move with sentiment, cycles, and liquidity conditions, so it may drift away from fundamentals. Valuation methods compare these perspectives to frame context.
Note that Haemonetics' intrinsic value and market price are different measures derived from different inputs. Analysis often considers earnings, revenue quality, fundamentals, technical signals, competition, and analyst coverage. By contrast, market price reflects the level where buyers and sellers transact.